Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

@article{Pfaller2006InterpretiveBF,
  title={Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.},
  author={Michael A. Pfaller and Daniel J. Diekema and Daniel Joseph Sheehan},
  journal={Clinical microbiology reviews},
  year={2006},
  volume={19 2},
  pages={435-47}
}
Developing interpretive breakpoints for any given organism-drug combination requires integration of the MIC distribution, pharmacokinetic and pharmacodynamic parameters, and the relationship between in vitro activity and outcome from both in vivo and clinical studies. Previously, the Subcommittee for Antifungal Testing of the Clinical and Laboratory Standards Institute (CLSI [formerly National Committee for Clinical Laboratory Standards]) proposed MIC interpretive breakpoints for fluconazole… CONTINUE READING
105 Citations
103 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 105 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 103 references

Similar Papers

Loading similar papers…